Zimmer Biomet Holdings (XSWX:ZBH) Cyclically Adjusted Revenue per Share: CHF33.76 (As of Mar. 2026)


XSWX:ZBH Zimmer Biomet Holdings Inc XSWX:ZBH
72 GF Score
Price CHF71.50
GF Value CHF101.16
! 3 Warning Signs
View Full Analysis

What is Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share?

Zimmer Biomet Holdings XSWX:ZBH 72 Cyclically Adjusted Revenue per Share is CHF33.76 as of Mar. 2026. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF101.16. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Zimmer Biomet Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was CHF8.390. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is CHF33.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Zimmer Biomet Holdings's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Zimmer Biomet Holdings was 11.30% per year. The lowest was 3.00% per year. And the median was 8.10% per year.

As of today (2026-07-10), Zimmer Biomet Holdings's current stock price is CHF71.50. Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was CHF33.76. Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is 2.12.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.08. The lowest was 1.89. And the median was 3.50.


Zimmer Biomet Holdings  (XSWX:ZBH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=71.50/33.76
=2.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Zimmer Biomet Holdings was 5.08. The lowest was 1.89. And the median was 3.50.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Related Terms


Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Zimmer Biomet Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Chart

Zimmer Biomet Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.67 33.66 32.77 43.36 39.00

Zimmer Biomet Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.07 51.57 31.64 39.00 33.76

XSWX:ZBH vs STE, PEN, GMED: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zimmer Biomet Holdings Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Zimmer Biomet Holdings's Cyclically Adjusted PS Ratio falls into.


XSWX:ZBH
72GF Score
Zimmer Biomet Holdings Inc XSWX:ZBH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zimmer Biomet Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Zimmer Biomet Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.39/330.2130*330.2130
=8.390

Current CPI (Mar. 2026) = 330.2130.

Zimmer Biomet Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 9.403 241.018 12.883
201609 8.791 241.428 12.024
201612 10.046 241.432 13.740
201703 9.726 243.801 13.173
201706 9.265 244.955 12.490
201709 8.554 246.819 11.444
201712 10.007 246.524 13.404
201803 9.348 249.554 12.369
201806 9.714 251.989 12.729
201809 8.659 252.439 11.327
201812 10.065 251.233 13.229
201903 9.604 254.202 12.476
201906 9.528 256.143 12.283
201909 9.056 256.759 11.647
201912 10.047 256.974 12.910
202003 8.287 258.115 10.602
202006 5.640 257.797 7.224
202009 8.466 260.280 10.741
202012 5.085 260.474 6.446
202103 7.084 264.877 8.831
202106 7.597 271.696 9.233
202109 7.385 274.310 8.890
202112 7.791 278.802 9.228
202203 7.357 287.504 8.450
202206 8.220 296.311 9.160
202209 7.728 296.808 8.598
202212 8.073 296.797 8.982
202303 8.054 301.836 8.811
202306 8.020 305.109 8.680
202309 7.512 307.789 8.059
202312 8.047 306.746 8.663
202403 8.141 312.332 8.607
202406 8.410 314.175 8.839
202409 7.613 315.301 7.973
202412 9.019 315.605 9.436
202503 8.447 319.799 8.722
202506 8.519 322.561 8.721
202509 8.015 324.800 8.149
202512 9.039 324.054 9.211
202603 8.390 330.213 8.390

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of CHF33.76 mean?
Zimmer Biomet Holdings (XSWX:ZBH) has a Cyclically Adjusted Revenue per Share of CHF33.76 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors.
Is Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share too high?
Zimmer Biomet Holdings' current Cyclically Adjusted Revenue per Share is CHF33.76. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share compare to STE and PEN?
Zimmer Biomet Holdings' Cyclically Adjusted Revenue per Share of CHF33.76 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zimmer Biomet Holdings and its competitors. Zimmer Biomet Holdings's current Cyclically Adjusted Revenue per Share is CHF33.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current Cyclically Adjusted Revenue per Share of CHF33.76. The stock's GF Value™ is CHF101.16, compared to a current price of CHF71.50 — trading 29.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is CHF33.76. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current Cyclically Adjusted Revenue per Share is CHF33.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?

Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued. The current stock price of CHF71.50 is trading 29.3% below its estimated GF Value™ of CHF101.16.

Key valuation signals for XSWX:ZBH:

  • Cyclically Adjusted Revenue per Share: CHF33.76
  • GF Value™: CHF101.16 vs. price of CHF71.50 (29.3% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zimmer Biomet Holdings Business Description

Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score

Get the complete analysis for XSWX:ZBH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF71.50
Price
CHF101.16
GF Value